Abstract
EE506 Budget Impact and Cost-Utility Analysis of Nivolumab Plus Ipilimumab in First-Line Treatment of Advanced Renal Cell Cancer (aRCC) in Costa Rica
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have